<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03267108</url>
  </required_header>
  <id_info>
    <org_study_id>PULSE-PHPF-001</org_study_id>
    <nct_id>NCT03267108</nct_id>
  </id_info>
  <brief_title>Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2)</brief_title>
  <official_title>A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL STUDY TO ASSESS THE SAFETY AND EFFICACY OF PULSED, INHALED NITRIC OXIDE (iNO) IN SUBJECTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH PULMONARY FIBROSIS ON LONG TERM OXYGEN THERAPY (PART 1 AND PART 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bellerophon Pulse Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bellerophon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bellerophon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2b, randomized, double-blind, placebo-controlled clinical study to assess the safety
      and efficacy of pulsed, inhaled nitric oxide (iNO) versus placebo in subjects with pulmonary
      fibrosis on long term oxygen therapy (Part 1 and Part 2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase 2b, randomized, double-blind, placebo-controlled clinical study to assess the safety
      and efficacy of pulsed, inhaled nitric oxide (iNO) versus placebo in subjects with and
      without pulmonary hypertension associated with pulmonary fibrosis on long term oxygen therapy
      (Part 1 and Part 2).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 29, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 Minute Walk Distance (6MWD)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in 6MWD from baseline to Week 8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Right Ventricular Function (RVF)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in RVF as measured by RV Tei index and RV free wall longitudinal strain from baseline to Week 8</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Nadir SpO2</measure>
    <time_frame>8 weeks</time_frame>
    <description>Difference in Nadir SpO2 during 6MWT from baseline to Week 8</description>
  </other_outcome>
  <other_outcome>
    <measure>Oxygen desaturation</measure>
    <time_frame>8 weeks</time_frame>
    <description>Difference in oxygen desaturation during 6MWT from baseline to Week 8</description>
  </other_outcome>
  <other_outcome>
    <measure>Distance Saturation Product (DSP)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Difference in DSP from baseline to Week 8</description>
  </other_outcome>
  <other_outcome>
    <measure>Integral Distance Saturation Product (IDSP)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Difference in IDSP from baseline to Week 8</description>
  </other_outcome>
  <other_outcome>
    <measure>Activity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Difference in Activity as measured by activity monitoring from baseline to Week 8</description>
  </other_outcome>
  <other_outcome>
    <measure>Dyspnea</measure>
    <time_frame>8 weeks</time_frame>
    <description>Difference in Dyspnea as measured by UCSD Shortness of Breath (SOB) questionnaire from baseline to Week 8</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life</measure>
    <time_frame>8 weeks</time_frame>
    <description>Difference in disease-specific Quality of Life as measured by St. George Respiratory questionnaire (SGRQ) from baseline to Week 8</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pulmonary Fibrosis</condition>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part 1: Placebo at a dose setting of 30 mcg/kg IBW/hr for up to 24 hours per day for 1 week run-in period and 8 week treatment period.
Part 2: iNO at a dose setting of 30 mcg/kg IBW/hr for up to 24 hours per day for open label treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled Nitric Oxide 30 mcg/kg IBW/hr</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: Placebo at a dose setting of 30 mcg/kg IBW/hr for up to 24 hours per day for 1 week run-in period followed by iNO at a dose setting of 30 mcg/kg IBW/hr for up to 24 hours per day for the 8 week treatment period.
Part 2: iNO at a dose setting of 30 mcg/kg IBW/hr for up to 24 hours per day for open label treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Nitric Oxide</intervention_name>
    <description>Inhaled Nitric Oxide 30 mcg/kg IBW/hr for treatment randomization period (Day 0 to Week 8). Continued open label treatment is available following completion of randomized treatment period.</description>
    <arm_group_label>Inhaled Nitric Oxide 30 mcg/kg IBW/hr</arm_group_label>
    <other_name>iNO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed Consent Form (and assent as appropriate) prior to the initiation of
             any study mandated procedures or assessments.

          2. Diagnosed with pulmonary fibrosis by high resolution CT scan performed in the 6 months
             prior to screening associated with one of the following conditions and confirmed using
             guidelines, as per American Thoracic Society (ATS) / European Respiratory Society
             (ERS) / Japanese Respiratory Society (JRS) / Latin American Thoracic Association
             (ALAT):

             2.1 Major IIPs (idiopathic interstitial pneumonias) diagnosis or suspected as one of
             the following:

               -  Idiopathic pulmonary fibrosis

               -  Idiopathic nonspecific interstitial pneumonia

               -  Respiratory bronchiolitis-interstitial lung disease

               -  Desquamative interstitial pneumonia

               -  Cryptogenic organizing pneumonia

               -  Acute interstitial pneumonia

               -  Rare IIPs diagnosis by one of the following:

               -  Idiopathic lymphoid interstitial pneumonia

               -  Idiopathic pleuroparenchymal fibroelastosis

               -  Unclassifiable idiopathic interstitial pneumonias

             2.2 Chronic hypersensitivity pneumonitis

             2.3 Occupational lung disease

          3. At least 50% of the subjects will have confirmed intermediate or high probability of
             pulmonary hypertension as determined by echocardiography according to the 2015 ESC/ERS
             Guidelines for Diagnosis and Treatment of Pulmonary Hypertension.

          4. Have been using oxygen therapy by nasal cannula for at least 4 weeks prior to the
             screening run-in period.

          5. 6MWD ≥ 100 meters and ≤ 450 meters prior to randomization.

          6. WHO Functional Class II-IV

          7. Forced Vital Capacity ≥ 40% predicted within last 6 months prior to screening the
             screening run-in period.

          8. For at least 1 week prior to Baseline/Randomization, subjects must demonstrate the
             ability to consistently use the device greater than 12 hrs/day in the opinion of the
             Investigator.

          9. Female subjects of childbearing potential must have a negative pre-treatment pregnancy
             test (serum or urine). All female subjects should take adequate precaution to avoid
             pregnancy.

         10. Subjects must have completed at least 1 week of activity monitoring prior to the
             Baseline/Randomization visit.

         11. Age between 18 and 80 years (inclusive)

         12. Subject should be clinically stable for at least 4 weeks prior to
             Baseline/Randomization in the opinion of the Principal Investigator.

        Exclusion Criteria:

          1. Demonstrate symptomatic rebound defined as significant cardiopulmonary instability,
             such as systemic arterial oxygen desaturation, hypoxemia, bradycardia, tachycardia,
             systemic hypotension, shortness of breath, near-syncope, and syncope, occurring within
             1 hour of acute iNO during rebound testing

          2. Episodes of disease worsening within 1 month prior to Baseline/Randomization

          3. Use of any type of intravenous or subcutaneous prostacyclin therapies

          4. Subjects receiving riociguat

          5. Acute or chronic physical impairment (other than dyspnea due to PF) that would limit
             the ability to comply with study procedures or adherence to therapy (i.e., 6MWT),
             including carrying and wearing the pulsed delivery device per study protocol, or
             medical problem(s) likely to preclude completion of the study

          6. Pregnant or breastfeeding females at Screening

          7. Administered L-arginine within 1 month prior to Screening

          8. The concurrent use of the INOpulse device with a continuous positive airway pressure
             (CPAP), Bilevel positive airway pressure (BPAP), or any other positive pressure
             device.

          9. Use of investigational drugs or devices within 1 month prior to Screening (other than
             acute vasodilator testing with iNO)

         10. Any underlying medical or psychiatric condition that, in the opinion of the
             Investigator, makes the subject an unsuitable candidate for the study including unable
             to complete 6MWT.

         11. Any subject who has been enrolled in any previous clinical study with inhaled NO
             administered through pulse delivery

         12. Evidence of any connective tissue disease in the last 6 months prior to screening in
             the opinion of the Principal Investigator

         13. Evidence of clinically significant Combined Pulmonary Fibrosis and Emphysema (CPFE) in
             the opinion of the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah Quinn, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bellerophon Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra Hankins</last_name>
    <phone>908-574-4715</phone>
    <email>sandra.hankins@bellerophon.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Georgene Nathan, MS</last_name>
    <phone>908-574-4711</phone>
    <email>georgene.nathan@bellerophon.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California Davis Health</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Macey Sockolov, CCRP</last_name>
      <phone>916-734-1554</phone>
      <email>mlsockolov@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Roblee Allen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Denver Anschutz Medical Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colton Carter</last_name>
      <phone>303-724-7938</phone>
    </contact>
    <contact_backup>
      <last_name>Cheryl Abbott, RN, CCRP</last_name>
      <phone>303-724-7466</phone>
    </contact_backup>
    <investigator>
      <last_name>Todd Bull, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kris Eliopoulos</last_name>
      <phone>303-270-2622</phone>
    </contact>
    <investigator>
      <last_name>Amy Olson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle Simonet, MA, CCRP</last_name>
      <phone>305-243-3728</phone>
    </contact>
    <investigator>
      <last_name>Roger Alvarez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Florida Pulmonary Group</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Foust, CCRC</last_name>
      <phone>407-841-1100</phone>
      <phone_ext>135</phone_ext>
      <email>sfoust@cfpulmonary.com</email>
    </contact>
    <investigator>
      <last_name>Syed Mobin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Healthcare</name>
      <address>
        <city>Austell</city>
        <state>Georgia</state>
        <zip>30106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheila Greene, MSA</last_name>
      <phone>770-745-1404</phone>
      <phone_ext>2</phone_ext>
      <email>sheila.greene@piedmont.org</email>
    </contact>
    <investigator>
      <last_name>Amy Case, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candace Flaherty, CCRP</last_name>
      <phone>734-936-8301</phone>
      <email>cflah@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christi Getty</last_name>
      <phone>734-232-5844</phone>
      <email>cgetty@med.umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Elizabeth Belloli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Lung Research Center, LLC</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Shipp, RRT</last_name>
      <phone>314-682-3653</phone>
      <email>Anna.Shipp@stlukes-stl.com</email>
    </contact>
    <contact_backup>
      <last_name>Kathleen McNulty, MHS</last_name>
      <phone>314-682-3653</phone>
      <email>Kathleen.McNulty@stlukes-stl.com</email>
    </contact_backup>
    <investigator>
      <last_name>Neil A Ettinger, MD, FACCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordyn DeMartino</last_name>
      <phone>843-792-8092</phone>
      <email>demartij@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Rahul Argula, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Del Greco, MSN, RN</last_name>
      <phone>615-343-7068</phone>
      <email>james.del.greco@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>James Loyd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Sciences</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Sweeten</last_name>
      <phone>801-581-5811</phone>
    </contact>
    <investigator>
      <last_name>MaryBeth Scholand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Heart and Vascular Institute Advanced Lung Disease Clinic</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serina Zorrilla, RN</last_name>
      <phone>703-776-6147</phone>
      <email>serina.zorrilla@inova.org</email>
    </contact>
    <contact_backup>
      <last_name>Edwinia Battle, RN</last_name>
      <phone>703-776-3067</phone>
      <email>edwinia.battle@inova.org</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher King, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates of Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betsy Daniel, CCRC</last_name>
      <phone>804-288-5945</phone>
      <email>bdaniel@paraccess.com</email>
    </contact>
    <investigator>
      <last_name>Shilpa Johri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2017</study_first_submitted>
  <study_first_submitted_qc>August 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2017</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Fibrosis</keyword>
  <keyword>PF</keyword>
  <keyword>Pulmonary Hypertension</keyword>
  <keyword>Inhaled Nitric Oxide</keyword>
  <keyword>iNO</keyword>
  <keyword>Long Term Oxygen Therapy</keyword>
  <keyword>Oxygen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

